Clopidogrel
P2Y12 Inhibitor (Antiplatelet)- Drug Class
- P2Y12 Inhibitor (Antiplatelet)
- Mechanism of Action (MOA)
- Irreversibly blocks the platelet P2Y12 ADP receptor → inhibits aggregation.
- Black Box Warning
- Diminished effectiveness in CYP2C19 poor metabolizers.
- Clinical Notes
- ACS and post-stent (dual antiplatelet with aspirin). Prodrug — activity reduced by CYP2C19 loss-of-function and some PPIs (omeprazole).
- Source
- FDA label
Sources
Reviewed September 2026- FDA label — FDA / DailyMed
Checked against the guideline or standard reference the exam keys to. If it has moved, use Report an error below.
Used for
Same family
Got a pharmacology lecture that covers Clopidogrel? Turn it into flashcards and board-style questions, free. Drop it on the home page
All pharmacology